C12-r8 (lauric acid–octaarginine)
Sequence: C12-r8 (D-type octaarginine; lauric acid coupled to N-terminus of D-octaarginine)
| Experiment Id | EXP001808 |
|---|---|
| Paper | Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of |
| Peptide | C12-r8 (lauric acid–octaarginine) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 400 nM miR-132 mimic (final, in Opti-MEM; 4 h) |
| Mixing Ratio | N/P (C12-r8:RNA) = 4:1; polymer envelopment stepwise |
| Formulation Format | Enveloped nanocomplex (ENCP): core C12-r8/miRNA nanocomplex electrostatic, shell HA |
| Formulation Components | C12-r8 complexed with miR-132 mimic at N/P 4:1 (core NCP), then enveloped with HA (0.5 mL of 1 mg/mL per 1 mL NCP) | Enveloping polymer: Hyaluronic acid (HA, ~57 kDa) |
| Size Nm | 106.00 |
| Zeta Mv | -24.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | CHO cells (4 h incubation) |
| Animal Model | |
| Administration Route | |
| Output Type | Cellular uptake/internalization (qPCR of miR-132 levels after incubation) |
| Output Value | ~11,000-fold increase vs endogenous miR-132 (higher than RNAiMAX) |
| Output Units | |
| Output Notes | qPCR quantification after incubation; compared vs PEG-PGA ENCPs and RNAiMAX. |
| Toxicity Notes | |
| Curation Notes |